Journal: Frontiers in Immunology
Article Title: CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs
doi: 10.3389/fimmu.2025.1513009
Figure Lengend Snippet: Anti-HLA-A2 CXCR5 + CAR-Tregs do not kill transplanted islets. (A) Experimental design. Five hundred HLA-A2 + pancreatic islets were isolated from HLA-A2 transgenic NSG mice and transplanted under the kidney capsule in HLA-A2 - NSG mice treated with streptozotocin to induce diabetes. Once glycemic control was achieved, mice were injected with 2x10 6 of anti-HLA-A2 CXCR5 + CAR-T conv or CAR-Tregs or UT Tregs. Glycemia was monitored in the blood and when reached values >250 mg/dl, the graft was considered rejected. Mice treated with Tregs underwent nephrectomy 30 days after the cell injection. (B) Blood glucose monitoring in transplanted mice assessed with a glucometer. TX = graft. (C) Weight monitoring in transplanted mice expressed in grams. (D) Percentage of circulating human CD45 + cells assessed by flow cytometry at different time points. (E) Frequency of human CD45 + cells in the spleen (SPL) and the graft (TX) at euthanasia, assessed by flow cytometry. Frequency of CAR + (F) and CXCR5 + (G) cells in the spleen (SPL) and the graft (TX) at euthanasia, assessed by flow cytometry. For this experiment we employed a total of 5 animals in each group in two independent experiments, indicated by the square and the round symbols, respectively.
Article Snippet: Pancreatic islets from NSG.HLA-A2 transgenic mice (NSG-HLA-A2/HHD, Jackson Laboratories, Bar Harbor, ME) were isolated as previously described ( ).
Techniques: Isolation, Transgenic Assay, Control, Injection, Flow Cytometry
